How do I treat poor erection quality and lack of durability?

Penile hardness and durability during sexual activity—often referred to clinically as erectile rigidity and maintenance—are essential components of satisfactory erectile function. If you're experiencing difficulty achieving or sustaining a firm, durable erection (i.e., insufficient rigidity for penetration or premature loss of erection), this may indicate erectile dysfunction (ED), a common but treatable condition.

First, it’s important to recognize that occasional variability in erection quality is normal and can be influenced by stress, fatigue, alcohol intake, or situational anxiety. However, persistent or recurrent issues—especially if present for more than three months—warrant clinical evaluation. Underlying causes may include vascular insufficiency (e.g., atherosclerosis, hypertension), metabolic conditions (e.g., diabetes mellitus, dyslipidemia), hormonal imbalances (e.g., low testosterone, hyperprolactinemia), neurological disorders, psychological factors (e.g., depression, performance anxiety), or medication side effects (e.g., SSRIs, antihypertensives).

Evidence-based management begins with a thorough history and physical examination, often supplemented by laboratory testing (e.g., fasting glucose, lipid panel, total and free testosterone, prolactin, thyroid-stimulating hormone). Lifestyle optimization—including smoking cessation, regular aerobic exercise, weight management, and moderation of alcohol—is foundational and can significantly improve endothelial function and erectile physiology.

First-line pharmacologic treatment typically involves oral phosphodiesterase type 5 inhibitors (PDE5is) such as sildenafil, tadalafil, or vardenafil. These agents enhance nitric oxide–mediated smooth muscle relaxation in the corpora cavernosa, facilitating increased arterial inflow and veno-occlusive trapping—thereby improving both rigidity and duration. Tadalafil offers the advantage of longer half-life (up to 36 hours), which may support spontaneity and sustained response.

For patients who do not respond adequately to PDE5is—or who have contraindications—second-line options include intracavernosal injection therapy (e.g., alprostadil), intraurethral alprostadil, vacuum erection devices, or, in select cases, penile prosthetic surgery. Emerging adjunctive strategies—such as low-intensity shockwave therapy (Li-ESWT)—are under active investigation for vasculogenic ED, though current evidence remains limited and not yet standard-of-care.

Importantly, ED can serve as an early warning sign of systemic cardiovascular disease. Therefore, comprehensive assessment should also address modifiable cardiovascular risk factors. A urologist or sexual medicine specialist can provide individualized diagnosis and management, integrating medical, behavioral, and relational considerations for optimal outcomes.